peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical to Host Conference Call to Provide Fourth Quarter and Full Year 2016 Business Update

9 Feb 2017, 08:30
On 15 February 2017, at 08:00 CET, Hansa Medical will publish its report for the fourth quarter and full year 2016. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 14:00 CET. The event will be hosted by Hansa Medical’s CEO and President, Göran Arvidson, and the presentation will be held in English.

Slides used in the presentation will be live on the Company’s website during the call under Events & Webcast and will be made available after the call.

To participate in the telephone conference, please call:

SE: +46 (0) 856 642 692

UK: +44 (0) 2030 089 802

US: +1 855 753 2235

A link to audio cast can be found on the Hansa Medical website under Events & Webcast or here.

Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46707175477

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner:
Mobile: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is a proprietary antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.